Stock Financial Ratios, Dividends, Split History

AVXS / AveXis, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price217.83
Volume884,100.00
Market Cap ($M)7,999.89
Enterprise Value ($M)7,675.78
Book Value / Share9.06
Price / Book24.04
NCAV ($M)273.60
NCAV / Share7.45
Price / NCAV29.24
Share Statistics
Common Stock Shares Outstanding 32,090,000
Common Shares Outstanding 36,725,399
Scoring Models
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.66
Return on Assets (ROA)-0.81
Return on Equity (ROE)-0.89
Balance Sheet (mrq) ($M)
Assets391.58
Liabilities58.84
Quick Ration/a
Current Ratio5.70
Income Statement (mra) ($M)
Revenues0.00
Operating Income-220.37
Net Income-218.05
Earnings Per Share Basic And Diluted-7.28
Cash Flow Statement (mra) ($M)
Cash From Operations-157.38
Cash from Investing-32.05
Cash from Financing-32.05
Identifiers and Descriptors
CUSIP05366U100
Central Index Key (CIK)1652923

Split History

Stock splits are used by AveXis, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...

Related News Stories

Bluebird Bio: Gene Therapy Best In Class

2018-05-16 seekingalpha
The current quarterly cash burn remains modest leaving most of the group with enough capital to operate through 3 to 5 years. (96-3)

Options Traders Expect Huge Moves in AveXis (AVXS) Stock

2018-05-11 zacks
Investors in AveXis, Inc. (AVXS - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the May 18, 2018 $100 Put had some of the highest implied volatility of all equity options today. (377-0)

Pushing Preclinical: Wave Of Early-Stage Biotech IPOs Tests Investor Risk Appetite

2018-05-09 seekingalpha
Biotechs are among the most risky of IPOs due to the binary nature of the success… or failure of their drugs. In the past, most biotechs delayed public offerings until they at least showed clinical evidence of their safety or efficacy. (69-2)

Should iShares Morningstar Small-Cap ETF (JKJ) Be on Your Investing Radar?

2018-05-08 zacks
Looking for broad exposure to the Small Cap Blend segment of the US equity market? You should consider the iShares Morningstar Small-Cap ETF (JKJ - Free Report) , a passively managed exchange traded fund launched on 06/28/2004. (16-0)

Your Daily Pharma Scoop: Takeda Acquisitions, Concert Trial Update, Sangamo Offering

2018-04-26 seekingalpha
As I was telling Brian Bain of DIY Investing yesterday in an interview (a part of their DIY Summit - see here), there’s a lot of talk going on about repatriated American tax dollars set to start a boom in M&A. However, quietly in the background, these large Japanese companies are scooping up major US/EU biotech. Now it is Takeda (OTCPK:TKPYY), which acquired/is about to acquire two important global companies very soon. (210-1)

CUSIP: 05366U100